In general, our findings suggested that CPNE1 might potentially act as a prognostic biomarker in ccRCC and highlighted the potential value of the CPNE1/EGFR/STAT3 axis as a promising target for combating ccRCC progression. Here, EGFR is linked to nonpapillary renal cell carcinoma.